GlassScriptPhysician profile
Sachin Soni
NPI 1205169380
$4,357.55
in general payments reported to CMS, 2019-2025
25 companies · $712 in 2025
The $712 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $477 · 2021: $822 · 2022: $400 · 2023: $480 · 2024: $999 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,157 · Education: $32.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,157.32 |
| Education | $32.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $673.97 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $643.55 | 2021-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $356.00 | 2020-2025 | Acthar |
| Opko Pharmaceuticals, LLC | $293.69 | 2019-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $257.53 | 2021-2025 | Lupkynis |
| Akebia Therapeutics INC | $222.95 | 2021-2025 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $203.58 | 2019-2025 | Veltassa |
| Calliditas Therapeutics US INC. | $190.26 | 2023-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $187.49 | 2022-2025 | |
| Silk Road Medical, INC. | $182.66 | 2020 | |
| Amgen INC. | $176.91 | 2020-2024 | Krystexxa, Tavneos |
| Novartis Pharmaceuticals Corporation | $176.78 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $138.76 | 2019-2024 | Velphoro |
| Medtronic Vascular, INC. | $125.69 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.35 | 2021-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $78.33 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $74.46 | 2024-2025 | Ozempic |
| Horizon Therapeutics Plc | $70.33 | 2021-2023 | Krystexxa |
| Mallinckrodt Enterprises LLC | $44.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.90 | 2024-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $33.29 | 2021 | |
| Ascendis Pharma Endocrinology INC | $28.25 | 2025 | Yorvipath |
| Glaxosmithkline, LLC. | $19.31 | 2021 | |
| Genzyme Corporation | $18.15 | 2022 | |
| Shield Therapeutics INC | $16.86 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sachin Soni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.